## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 5

VALEANT PHARMACEUTICALS INTERNATIONAL

Form 5 Fe F

February 10,	2005								
FORM	15						OMB AF	PROVAL	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION								3235-0362	
Check this box if washington, D.C. 20549 no longer subject							Expires:	January 31, 2005	
Form 4 or 5 obligatic may contin	to Section 16. Form 4 or Form 5 obligations may continue. ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							verage rs per 1.0	
See Instruct 1(b).		uant to S	Section 16	(a) of the Se	ecurities Exchang	e Act of 1934,			
Form 3 Ho	oldings Section 17(a)	) of the I	Public Uti	lity Holding	Company Act of	1935 or Section			
Reported Form 4 Transactio Reported	ons	30(h)	of the Inv	estment Con	mpany Act of 194	0			
	ddress of Reporting P DT EDWARD A	erson <u>*</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol VALEANT PHARMACEUTICALS			5. Relationship of Reporting Person(s) to Issuer			
				ATIONAL		(Check all applicable)			
(Last)	(First) (M	iddle)	<ol> <li>Statement for Issuer's Fiscal Year Ended (Month/Day/Year)</li> <li>12/31/2004</li> </ol>			X Director Officer (give t below)		Owner r (specify	
3300 HYLA	ND AVENUE		12,01,20						
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Reporting			
						(check	applicable line)		
COSTA ME	ESA, CA 92620	5				_X_ Form Filed by O Form Filed by M Person			
(City)	(State) (Z	Zip)	Table	I - Non-Deriv	ative Securities Acq	uired, Disposed of,	or Beneficial	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any		3. Transaction Code (Instr. 8)	4. Securities Acquir (A) or Disposed of ( (Instr. 3, 4 and 5)	ed 5. Amount of	6. Ownership Form:	7. Nature of Indirect Beneficial Ownership (Instr. 4)	

(City)	(State) (2	Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acc (A) or Disposed (Instr. 3, 4 and 5 (A) or Amount (D)	of (D)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	Ownership Form:	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Dividend Equivalent Rights	07/28/2004	Â	A4	26 <u>(1)</u> A	\$ 17.13	26	D	Â	
Dividend Equivalent Rights	10/27/2004	Â	A4	22 <u>(1)</u> A	\$ 24.59	48	D	Â	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 2270 (9-02)

## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 5

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. of D S G E I S Fi (I
					(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships						
	Director	10% Owner	Officer	Other			
BURKHARDT EDWARD A 3300 HYLAND AVENUE COSTA MESA, CA 92626	ÂX	Â	Â	Â			
Signatures							
By: Michelle May For: Edward Burkhardt	02/04/2005						
**Signature of Reporting Person	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The dividend equivalent rights accrued on phantom stock that are subject to all the terms and conditions of the underlying phantom stock to which they relate.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.